1252 related articles for article (PubMed ID: 20659226)
21. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
22. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
Lian JS; Zeng LY; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD
World J Gastroenterol; 2013 Oct; 19(37):6278-83. PubMed ID: 24115827
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
Ze E; Baek EK; Lee JJ; Chung HW; Ahn DG; Cho HJ; Kwon JC; Kim HJ; Lee H
Clin Mol Hepatol; 2014 Sep; 20(3):267-73. PubMed ID: 25320730
[TBL] [Abstract][Full Text] [Related]
24. Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study.
Lee SJ; Yim HJ; Hwang SG; Seo YS; Kim JH; Yoon EL; Lee JM; Kim BH; Park SJ; Park YM; Kim HS; Lee SH; Ahn SH; Lee JI; Lee JW; Kim IH; Kim HS; Hong SP
Scand J Gastroenterol; 2013 Feb; 48(2):196-204. PubMed ID: 23194375
[TBL] [Abstract][Full Text] [Related]
25. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
Idilman R; Kaymakoglu S; Oguz Onder F; Ahishali E; Bektas M; Cinar K; Pinarbasi B; Karayalcin S; Badur S; Cakaloglu Y; Mithat Bozdayi A; Bozkaya H; Okten A; Yurdaydin C
J Viral Hepat; 2009 Apr; 16(4):279-85. PubMed ID: 19222742
[TBL] [Abstract][Full Text] [Related]
26. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment.
Kim HJ; Park SK; Yang HJ; Jung YS; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Choi KY
Clin Mol Hepatol; 2016 Sep; 22(3):350-358. PubMed ID: 27729626
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance.
Park JW; Kim HS; Seo DD; Jang JS; Shin WG; Kim KH; Jang MK; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK
J Viral Hepat; 2011 Oct; 18(10):e475-81. PubMed ID: 21914066
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance.
Seo SY; Kim IH; Sohn JY; Lee S; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG
Intervirology; 2014; 57(1):8-16. PubMed ID: 23988634
[TBL] [Abstract][Full Text] [Related]
30. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
[TBL] [Abstract][Full Text] [Related]
31. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the 48-week efficacy of Lamivudine plus Adefovir or Entecavir monotherapy in patients with HBeAg negative hepatitis following Lamivudine treatment failure.
Zhang Q; Zhang L; Xing Y; Qin Y; Liu G
Acta Gastroenterol Belg; 2019; 82(1):31-34. PubMed ID: 30888751
[TBL] [Abstract][Full Text] [Related]
33. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
Sheng YJ; Liu JY; Tong SW; Hu HD; Zhang DZ; Hu P; Ren H
Virol J; 2011 Aug; 8():393. PubMed ID: 21824397
[TBL] [Abstract][Full Text] [Related]
34. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
[TBL] [Abstract][Full Text] [Related]
36. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
37. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
Son CY; Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
Liver Int; 2012 Aug; 32(7):1179-85. PubMed ID: 22452737
[TBL] [Abstract][Full Text] [Related]
38. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
[TBL] [Abstract][Full Text] [Related]
39. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
[TBL] [Abstract][Full Text] [Related]
40. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
Liaw YF; Lee CM; Chien RN; Yeh CT
J Viral Hepat; 2006 Apr; 13(4):250-5. PubMed ID: 16611191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]